Dabur India. Neutral. Rs93

Similar documents
Dabur India. CMP: INR106 TP: INR94 Neutral

Godrej Consumer Products

Dabur India. CMP: INR130 TP: INR135 Neutral

Shriram Transport Finance

Maruti Suzuki. CMP:Rs1,327 TP:Rs1,625 Buy

ITC. Buy. Rs169. 3QFY11 Results Update 19,008 5,697

Asian Paints. CMP: INR2,722 TP: INR3,161 Buy

Previous Recommendation: Buy

Previous Recommendation: Neutral

Reliance Communications

Hindustan Unilever. CMP:INR324 TP:INR302 Neutral

Titan Industries. CMP: INR222 TP: INR220 Neutral

Pidilite Industries. CMP: INR164 TP: INR186 Buy

Godrej Consumer Products

Previous Recommendation: Neutral QUARTERLY PERFORMANCE (INDIAN GAAP)

Godrej Consumer Products

Unitech. CMP: INR20 TP: INR30 Buy

Larsen & Toubro. CMP: INR1,160 TP: INR1,417 Buy

BGR Energy. Buy. Target price: Rs958. Large EPC order expected in FY11; order-book to double to Rs200b

BGR Energy. CMP: INR284 TP: INR296 Neutral

Jubilant Foodworks. CMP: INR1,189 TP: INR1,0541,054 Neutral

Pantaloon Retail. CMP: INR177 TP: INR192 Neutral

CMP: INR121 TP: INR193 Buy

Jubilant Foodworks. CMP: INR1,051 TP: INR1,054 Neutral

Larsen & Toubro. CMP: INR1,278 TP: INR1,380 Buy

Godawari Power & Ispat

Positive outlook for both JLR and domestic business. JLR's 1Q margins sustainable subject to stable forex; Buy

Godrej Consumer Products

Idea Cellular. CMP: INR81 TP: INR Under Review

Cummins India. CMP: INR430 TP: INR462 Neutral

Sanofi India. CMP: INR2,200 TP: INR1,848 Neutral

IDBI Bank. CMP: INR106 TP: INR121 Neutral

BGR Energy. CMP: INR266 TP: INR230 Neutral

BGR Energy. CMP: INR282 TP: INR253 Neutral

Kotak Mahindra Bank. CMP: INR495 TP: INR429 Neutral

Cummins India. Buy. Rs698. Encouraging long-term outlook, as parent looks at sourcing more from India; domestic sales to grow at a steady pace

IndusInd Bank. CMP: INR345 TP: INR419 Buy

Medium term profitability driven by commodity earnings

Sun Pharmaceuticals. CMP: INR554 TP: INR614 Neutral

Thermax. CMP: INR522 TP: INR414 Neutral

Canara Bank. CMP: INR419 TP: INR525 Buy

Hardick Bora

Jaiprakash Associates

NTPC CMP: INR169 TP: INR191 Buy

Dabur. Bargain hunting BUY COMPANY UPDATE 12 DEC CMP (as on 12 Dec 2013) Rs 168 Target Price Rs 192

Canara Bank. CMP: INR464 TP: INR645 Buy

Sanjay Jain Pavas Pethia

Punjab National Bank. CMP:INR1,103 TP:INR1,500 Buy

Tata Power. CMP: INR111 TP: INR92 Neutral

Niket Shah

Dabur India. Steady recovery in place; Accumulate. Source: Company Data; PL Research

Addressing key investor concerns. Dec-09

ITC. CMP: INR201 TP: INR230 Buy

Steel Authority of India

Idea Cellular. CMP: INR159 TP: INR200 Buy

Godrej Properties. CMP: INR595 TP: INR635 Neutral

Reliance Infrastructure CMP: INR528

CMP: INR401 TP: INR516 Buy. * After ESOP charges; # Axon consolidated in December 2008

Hindalco. CMP: INR113 TP: INR151 Buy

CMP: INR350 TP: INR375 Downgrade to Neutral

Sohail Halai Alpesh Mehta

Indiabulls Real Estate

Monnet Ispat. CMP: INR449 TP: INR518 Neutral

Dabur India. Share gains power growth, Accumulate. Source: Company Data; PL Research

Hardick Bora 4QCY12 Results Update Sector: Healthcare Sanofi India CMP: INR2,307 TP: INR2,015 Neutral

DABUR INDIA LIMITED RESEARCH

Axis Bank. CMP: INR1,008 TP: INR1,240 Buy

Oberoi Realty. CMP: INR264 TP: INR315 Buy

Petronet LNG. CMP: INR146 TP: INR205 Buy

Punjab National Bank. CMP: INR768 TP: INR963 Buy

Phoenix Mills. CMP: INR184 TP: INR255 Buy

Jinesh Gandhi Chirag Jain

Dabur India. Institutional Equities. 1QFY19 Result Update

Punjab National Bank. CMP: INR716 TP: INR950 Buy

Strides Arcolab. CMP: INR717 TP: INR829 Buy

Coal India CMP: INR348 TP: INR408 Buy

Dabur India Ltd. Q3FY18 Result Update Strong Volume led Domestic growth; IBD remains weak. Sector: FMCG CMP: ` 356. Recommendation: BUY

M&M Financial Services

BHEL. CMP: INR227 TP: INR233 Neutral

Sandipan Pal QFY13 Results Update Sector: Real Estate Unitech CMP: INR29 TP: INR44 Buy

Dabur India. Source: Company Data; PL Research

Maruti Suzuki. CMP: INR1,395 TP: INR1,730 Buy

Shree Renuka Sugars. CMP: INR41 TP: INR50 Buy

Siddharth Bothra

Shree Renuka Sugars. CMP: INR26 TP: INR45 Buy

Jinesh Gandhi Sandipan Pal

Axis Bank. CMP: INR1,119 TP: INR1,330 Buy

Hindustan Unilever. Q4FY18 Result Update Strong volume growth on weak base and uptick in rural. Sector: FMCG CMP: ` 1,516. Recommendation: HOLD

Hardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy

Amber Enterprises India Ltd

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Hardick Bora 4QFY13 Results Update Sector: Healthcare Dr Reddy's Laboratories CMP: INR2,026 TP: INR2,375 Buy

Punjab National Bank. CMP: INR940 TP: INR1,275 Buy

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

HFC NEUTRAL. Performance Highlights CMP. `678 Target Price - 1QFY2013 Result Update HFC. Investment Period - Key financials

Oberoi Realty. CMP: INR269 TP: INR320 Buy

Hindustan Unilever. Q1FY19 Result Update Maintaining strong volume trajectory on high base is the key. Sector: FMCG CMP: ` 1,644. Recommendation: HOLD

Shoppers Stop. CMP: INR339 TP: INR355 Neutral

Urban demand revives; Akzo gaining market share

GAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -

Transcription:

3QFY11 Results Update SECTOR: FMCG BSE SENSEX S&P CNX 18,022 5,417 Bloomberg DABUR IN Equity Shares (m) 1,738.0 52-Week Range (Rs) 112/79 1,6,12 Rel. Perf. (%) 5/-5/2 M.Cap. (Rs b) 160.8 M.Cap. (US$ b) 3.5 Rs93 Dabur India Neutral Key takeaways from the concall The management indicated that the current inflationary environment did not have a major impact on FMCG consumption although a better picture would emerge over the coming months. Shampoo de-growth was led by sharp price corrections (40% extra milliliters) taken by Dabur and other shampoo makers. The management indicated that the recent price war in the shampoo market impacted category margins by ~10%. Exposure to Egypt is limited to 3% of sales and the Egyptian plant doesn't service sales in neighboring countries. Hence the impact of the recent turmoil is not likely to be significant. Slowdown, competition in domestic business a concern; estimates unchanged: Dabur India has been facing strong headwinds in the domestic business, which is reflected in the deceleration in volume growth and input cost pressure. We believe Dabur's reliance on the international business for its profit growth is rising (~76% of incremental profits in 9MFY11). We expect this to increase due to consolidation of Hobi and Namaste acquisitions and faster growth in existing international business; we believe the international businesses should trade at a discount to the P/ E of the India centric business due to scalability, currency risk, country risk and acquisitions of lower growth/lower margin profile businesses. Our estimates are largely unchanged for FY11 and FY12 (2% downgrade in FY13 estimates) as the profit accretion from acquisitions is offset by lower margins in the domestic business and higher depreciation of the consolidated entity. The stock trades at 23.5x FY12E EPS of Rs3.9 and 19.8x FY13E EPS of Rs4.7. Maintain Neutral. Amnish Aggarwal (AmnishAggarwal@MotilalOswal.com); Tel:+9122 39825404/Nikhil Kumar (Nikhil.N@MotilalOswal.com); Tel: +922 39825120

Key takeaways from the concall The management indicated that the current inflationary environment had not had a major impact on FMCG consumption yet. The management indicated that FMCG product price increases had been lower than general inflation, which helped to improve relative affordability. However, a better picture will emerge over the coming months. The international business has been the strongest contributor to PAT accretion due to 20.3% sales growth and 23% EBITDA margins in 9MFY11. The management indicated that the SBU was likely to post 20%+ growth and ~25% EBITDA margins in coming years. Shampoo de-growth was led by sharp price corrections (40% extra milliliters) taken by Dabur and other shampoo players. Management indicated that the recent price war in the shampoo market impacted margins in the category by ~10%, but its market share had not contracted. It expects growth revival in FY11. Exposure to Egypt is limited to 3% of sales and the plant in Egypt doesn't service sales in neighboring countries. Hence the impact of recent turmoil is not likely to be significant. 3QFY11 results in line: international business accounts for ~60% of PAT accretion Consolidated sales grew 16.6% YoY to Rs10.8b helped by 10% volume growth, ~4% realization growth and the impact of the Hobi consolidation (3%). Gross margins contracted 300bp YoY to 51.6% due to a sharp increase in input costs and delay in taking price increases. However a cut in ad-spends (210bp), other expenditure (80bp) and staff costs (50bp) enabled EBITDA margin expansion of 30bp to 19.4%. Subsidiary sales grew 36% YoY (including the Hobi acquisition), led by a 220bp margin expansion. PAT grew 42.8%, accounting for ~60% of PAT accretion in 3QFY11. 16.6% sales growth (13.3% adjusted for Hobi) led by 14.6% volume growth 19.9 20.6 Net Sales (Rs m) 27.2 22.7 18.9 Grow th (% YoY) 19.3 16.0 14.7 16.6 14.0 13.5 16.0 13.0 14.6 12.0 17.0 13.5 10.0 Dec-08 Mar-09 Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10 Dec-10 Dec-08 Mar-09 Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10 Dec-10 7,787 7,317 7,683 8,480 9,262 8,488 9,165 9,728 10,800 Source: Company/MOSL 1 February 2011 2

Stringent cost control enables margin expansion 14.4 EBITDA (Rs m) EBITDA Margins (%) 18.1 17.9 17.7 15.9 20.7 19.1 19.1 14.9 20.9 19.4 Jun-08 Sep-08 Dec-08 Mar-09 Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10 Dec-10 871 1,248 1,290 1,296 1,182 1,754 1,773 1,620 1,367 2,028 2,095 Source: Company/MOSL Volume growth 10%; deceleration across major categories Dabur's sales grew 16.6% led by 10% volume growth and 4% price increases. Consolidation of Hobi Kozmetic from 7 October 2010 added 3% to overall sales. We highlight that volume growth of 10% is the lowest in the past 10 quarters and significantly lower than ~15% volume growth reported in 1HFY11. Dabur Consolidated Segmental: Margin contraction across categories except Foods Year Ended March 3QFY11 3QFY10 % Chg 9MFY11 9MFY10 % Chg Net Sales (Rs m) 10,878 9,323 16.7 29,926 25,607 16.9 Consumer Care 8,668 7,463 16.1 23,237 19,852 17.0 Consumer Health 813 714 13.8 2,291 2,027 13.0 Foods 1,124 866 29.8 3,684 3,002 22.7 Retail 58 28 104.6 138 68 Others 216 251-14.1 576 658-12.4 EBIT (Rs m) 2,654 2,372 24.0 7,211 6,366 13.0 Consumer Care 2,289 2,037 12.3 6,030 5,329 13.2 Consumer Health 186 179 4.2 528 525 0.6 Foods 196 150 30.2 698 524 33.3 Retail -20-24 -14.4-69 -71 Others 4 29-88.1 24 59-60.4 EBIT Margin (%) Consumer Care 26.4 27.3-0.9 25.9 26.8-0.9 Consumer Health 22.9 25.0-2.1 23.1 25.9-2.8 Foods 17.4 17.3 0.1 19.0 17.4 1.5 Retail - - - - - - Others 1.6 11.7-10.0 4.1 9.0-4.9 Source: Company/MOSL 3QFY11 sales growth decelerated across product segments except in skin care, foods and hair care. Rising inflation and competitive pressure in key segments will prevent a sharp increase in growth rates, at least in the medium term. Decelration in Major categories Category Growth (%) FY08 FY09 FY10 1QFY11 2QFY11 3QFY11 9MFY11 Hair Care 13.0 23.0 13.6 8.9 2.7 3.8 5.1 Health Supplements 14.6 11.0 20.4 43.0 29.4 12.7 23.7 Oral Care 15.0 5.0 11.5 20.2 10.4 9.4 13.2 Foods 19.0 23.0 20.0 21.2 21.4 42.0 27.7 Digestives 11.1 12.0 10.8 14.7 14.1 11.3 13.3 Skin care 4.1 14.0 33.2 12.4 9.6 18.0 14.2 Home Care 10.3 10.0 3.3 31.5 43.3 24.2 33.1 IBD 25.5 39.9 26.3 28.7 17.9 14.2 20.3 Source: Company/MOSL 1 February 2011 3

In 3QFY11, hair care sales grew ~3.8%, shampoo sales contracted 29%, and Amla hair oil sales grew only 6% (up 14.9% in 1HFY11). However, Anmol coconut and Vatika hair oil sales grew 6% and 18%, respectively. Oral care sales grew 9.4% in 3QFY11, led by 18.7% sales growth in the toothpaste segment. Dabur Red grew 20.5%, Babool by 19.6% and Meswak by 13.1%. Health supplements grew 12.7%, led by Chayawanprash (up 15.5% in 3QFY11), Dabur Honey grew 9% in 3QFY11 and Dabur Glucose was flat. Skin care grew 18% in 3QFY11, led by Gulabari. Fem bleaches reported acceleration in growth as sales grew 21% in 3QFY11 (12% in 1HFY11). Home Care reported sharply lower sales with 24% growth in 3QFY11 (37% in 1HFY11). Odonil was a key growth driver with 53% growth in 3QFY11. Foods sales increased 42%, led by Real (44%) and Activ (33%). Homemade grew 33.6% due to high demand for cooking pastes in the current inflationary environment. International business accounts for ~60% of PAT International business sales grew 14.2% YoY (constant currency sales up 19.2%) and sales growth declined from 23.3% in 1HFY11. EBITDA margins were 28% mainly due to benefits of scale. The international business and profits are growing at a faster clip than the domestic business. The international business accounted for ~60% of incremental consolidated PAT for Dabur India in 3QFY11. Dabur India completed the acquisition of Hobi Kozmetik group with effect from 8 October 2010, reporting sales of Rs279m and PAT of Rs10m (annualized sales of Rs1.1b and PAT of Rs40m against CY09 sales of US$27m, or Rs1.1b, and EBITDA margin of 14%). Dabur completed the acquisition of Namaste Labs and it would be consolidated in the 4QFY11 financials. Hobi and Namaste will increase the share of international business to 30%, weakening the case for Dabur as a pure proxy on Indian consumption. Slowdown/competition in domestic business a concern; estimates unchanged Dabur India's domestic business has been facing headwinds, reflected in deceleration in volume growth and input cost pressure. We believe Dabur's reliance on its international business for profit growth is rising (~76% of incremental profits in 9MFY11). We expect this to increase due to consolidation of the Hobi and Namaste acquisitions and faster growth in the international business. We believe international businesses will trade at a discount to P/E of the India centric business due to scalability, currency risk, country risk and acquisitions of lower growth/lower margin profile businesses. Our FY11 and FY12 estimates are largely unchanged (2% downgrade in FY13 estimates) as the profit accretion from acquisitions gets offset by lower margins in the domestic business and higher depreciation of the consolidated entity. The stock trades at 23.5x FY12E of Rs3.9 and 19.8x FY13E EPS of Rs4.6. Maintain Neutral. 1 February 2011 4

Dabur India: an investment profile Company description Dabur India is India's second largest FMCG company in terms of product portfolio. Dabur is a market leader in the Chyawanprash category and is increasing its presence in other traditional categories like hair care, oral care, household care and foods. Dabur's acquisition of Fem Care has given it a strategic presence in the high potential skin care segment. Key investment arguments Strong herbal positioning with little competition from MNCs in categories like hair oil, CHD and health supplements. Dabur has the second broadest product portfolio (after HUL) with a presence in high potential categories like skin care, hair care, oral care and health supplements. The company is likely to be under MAT for 7-8 years, resulting in tax savings. Key investment risks Dabur's standalone sales have been decelerating over the past three quarters and it has been highly dependant on international business for its PAT growth. We believe Dabur will face increasing competition in some key business segments: (1) toothpaste (likely entry of P&G), (2) hair oil (aggressive strategy of Marico and Emami), (3) shampoo (aggressive strategy of P&G, HUL and Garnier resulting in a squeeze in sales growth and margins) and (4) skin care (rising focus of MNCs on the mass to mid-premium segment). Recent developments Dabur increased prices by 4.1% YTD to offset input cost pressures. Dabur completed the acquisition of the Namaste group and the business will be consolidated from 4QFY11. Valuation and view Our EPS estimate is Rs3.2 for FY11, Rs3.9 for FY12 and Rs4.7 for FY13, implying a PAT CAGR of 20% over FY11-13. The stock trades at 23.5x FY12E EPS of Rs3.9 and 19.8x FY13E EPS of Rs4.6. Maintain Neutral. Sector view We have a cautious view on the sector given slow income growth in the economy, which might impact volumes and profit margins of companies. Companies with low competitive pressures and broad product portfolios will be able to better withstand a slowdown in a segment. Long term prospects appear bright, given rising incomes and low penetration. Comparative valuations Dabur Marico GCPL P/E (x) FY11E 28.6 27.2 26.7 FY12E 23.5 23.4 22.2 P/BV (x) FY11E 13.1 8.9 7.5 FY12E 10.0 6.8 6.6 EV/Sales (x) FY11E 4.0 2.5 3.8 FY12E 3.1 2.0 3.0 EV/EBITDA (x) FY11E 21.6 19.6 21.2 FY12E 17.5 15.7 16.6 EPS: MOSL forecast v/s Consensus (Rs) MOSL Consensus Variation Forecast Forecast (%) FY11 3.2 3.4-5.6 FY12 3.9 4.2-6.1 Target Price and Recommendation Current Target Upside Reco. Price (Rs) Price (Rs) (%) 93 93 - Neutral Stock performance (1 year) 115 Dabur Sensex - Rebased Shareholding Pattern (%) Dec-10 Sep-10 Dec-09 Promoter 68.7 68.7 69.1 Domestic Inst 7.8 8.1 10.4 Foreign 16.8 16.7 13.9 Others 6.6 6.5 6.6 105 95 85 75 Feb-10 May-10 Aug-10 Nov-10 Feb-11 1 February 2011 5

Financials and Valuation 1 February 2011 6

NOTES 1 February 2011 7

For more copies or other information, contact Institutional: Navin Agarwal. Retail: Manish Shah Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: reports@motilaloswal.com Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai 400 021 This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOSt or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. MOSt and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement Dabur India 1. Analyst ownership of the stock No 2. Group/Directors ownership of the stock No 3. Broking relationship with company covered No 4. Investment Banking relationship with company covered No This information is subject to change without any prior notice. MOSt reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOSt is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. 1 February 2011 8